Further correlative studies done to better apprehend the fundamental mechanism through which gut microbiota may impact systemic and anti-tumor immunity demonstrated that mice receiving R-FMT had higher levels of CD8+ T cells in their tumors as well as an increase in the number of CD45+ immune and CD8+ T cells in their guts [27]. The gene discussed is CD8A; the disease is neoplasm.